CN103463726B - 一种球囊扩张导管 - Google Patents
一种球囊扩张导管 Download PDFInfo
- Publication number
- CN103463726B CN103463726B CN201310364612.4A CN201310364612A CN103463726B CN 103463726 B CN103463726 B CN 103463726B CN 201310364612 A CN201310364612 A CN 201310364612A CN 103463726 B CN103463726 B CN 103463726B
- Authority
- CN
- China
- Prior art keywords
- actuator
- catheter
- micropin
- balloon structure
- sacculus dilating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 claims abstract description 76
- 238000002347 injection Methods 0.000 claims abstract description 39
- 239000007924 injection Substances 0.000 claims abstract description 39
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 35
- 241000258957 Asteroidea Species 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 67
- 230000000916 dilatatory effect Effects 0.000 claims description 45
- 229940079593 drug Drugs 0.000 claims description 26
- 230000005540 biological transmission Effects 0.000 claims description 22
- 230000007246 mechanism Effects 0.000 claims description 12
- -1 polyethylene Polymers 0.000 claims description 12
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 11
- 229910000077 silane Inorganic materials 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 claims description 10
- 238000011161 development Methods 0.000 claims description 9
- 229920002614 Polyether block amide Polymers 0.000 claims description 8
- 239000004677 Nylon Substances 0.000 claims description 7
- 229920001778 nylon Polymers 0.000 claims description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 6
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920001084 poly(chloroprene) Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 239000004642 Polyimide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002379 silicone rubber Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 238000002399 angioplasty Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013536 elastomeric material Substances 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000010959 steel Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- BHASHBRUGOYKMC-UHFFFAOYSA-N 1,2,3,4-tetraiodobenzene Chemical compound IC1=CC=C(I)C(I)=C1I BHASHBRUGOYKMC-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229960001025 iohexol Drugs 0.000 description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 2
- 229960004647 iopamidol Drugs 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 229960002603 iopromide Drugs 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- GDVNLLJNADMLLR-BBRMVZONSA-N Spergualin Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)C[C@@H](O)CCCCN=C(N)N GDVNLLJNADMLLR-BBRMVZONSA-N 0.000 description 1
- JBVZQDJNGFOSNX-UHFFFAOYSA-N Spergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CC(O)CCCCNC(=CN)N JBVZQDJNGFOSNX-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 108010017278 depsidomycin Proteins 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005077 saccule Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
实施例 | 类似球囊结构 | 两种弹性模量材料之差 | 收回次数/总次数 |
实施例1 | 哑铃形 | 1800 | 23/30 |
实施例2 | 哑铃形 | 0(相同弹性模量材料) | 20/30 |
实施例3 | 连续两个哑铃形 | 200 MPa | 25/30 |
实施例4 | 五角星形 | 1600MPa | 26/30 |
实施例5 | 四角星变形 | 800MPa | 29/30 |
实施例6 | 三角星变形 | 1200MPa | 30/30 |
实施例7 | 无凹陷普通球囊 | 0(相同弹性模量材料) | 14/30 |
实施例8 | 弯针注射导管 | 0(相同弹性模量材料) | 12/30 |
实施例9 | 可充胀医疗装置 | 0(相同弹性模量材料) | 10/30 |
微针数 | 药物含量μg | 药物回收量μg | 平均转载率 |
0 | 600 | 59.3±13.4 | 9.9% |
2 | 50.0 | 27.8±3.8 | 55.6% |
4 | 50.0 | 33±5.1 | 66% |
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310364612.4A CN103463726B (zh) | 2013-08-20 | 2013-08-20 | 一种球囊扩张导管 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310364612.4A CN103463726B (zh) | 2013-08-20 | 2013-08-20 | 一种球囊扩张导管 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103463726A CN103463726A (zh) | 2013-12-25 |
CN103463726B true CN103463726B (zh) | 2015-05-27 |
Family
ID=49788905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310364612.4A Active CN103463726B (zh) | 2013-08-20 | 2013-08-20 | 一种球囊扩张导管 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103463726B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104434258A (zh) * | 2014-11-28 | 2015-03-25 | 苏州亘科医疗科技有限公司 | 一种多功能球囊扩张导管 |
CN105999512B (zh) * | 2016-06-22 | 2023-02-21 | 厦门大学附属中山医院 | 一种可视动静脉内瘘溶栓器 |
CN108742959A (zh) * | 2018-04-21 | 2018-11-06 | 李皇德 | 一种血管球囊,球囊支架药物释放装置及其药物释放方法 |
CN113262381A (zh) * | 2021-07-02 | 2021-08-17 | 深圳麦普奇医疗科技有限公司 | 球囊扩张导管 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383385A (zh) * | 1999-01-15 | 2002-12-04 | 英特温什奈尔技术公司 | 保持住向定点区域送药的注射头所用的可充胀医疗装置 |
CN102781508A (zh) * | 2009-09-18 | 2012-11-14 | 因诺瓦斯克有限责任公司 | 能够进行低压球囊血管成形术且避免支架置入术的动脉粥样硬化斑块的血管成形术前锯齿化 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2328650B1 (en) * | 2008-08-26 | 2016-04-06 | Cook Medical Technologies LLC | Balloon catheters having a plurality of needles for the injection of one or more therapeutic agents |
US20130066257A1 (en) * | 2011-09-12 | 2013-03-14 | Boston Scientific Scimed, Inc. | Design of Interventional Cutting Balloon with Enhanced API Delivery Capability |
-
2013
- 2013-08-20 CN CN201310364612.4A patent/CN103463726B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383385A (zh) * | 1999-01-15 | 2002-12-04 | 英特温什奈尔技术公司 | 保持住向定点区域送药的注射头所用的可充胀医疗装置 |
CN102781508A (zh) * | 2009-09-18 | 2012-11-14 | 因诺瓦斯克有限责任公司 | 能够进行低压球囊血管成形术且避免支架置入术的动脉粥样硬化斑块的血管成形术前锯齿化 |
Also Published As
Publication number | Publication date |
---|---|
CN103463726A (zh) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11090467B2 (en) | Apparatus and methods for scaffolding | |
US8366661B2 (en) | Medical device with expandable body for drug delivery by capsules | |
CN211584835U (zh) | 一种药物球囊导管 | |
CN103463726B (zh) | 一种球囊扩张导管 | |
CN203989422U (zh) | 三腔双球囊扩张导管 | |
CN110548211B (zh) | 一种带封堵功能的药物球囊导管 | |
TWI746179B (zh) | 導管 | |
JP7137584B2 (ja) | 再狭窄の処置のための併用療法 | |
KR101396017B1 (ko) | 풍선 카테터 | |
CN106073942A (zh) | 一种支架及药物输送装置 | |
CN104857615A (zh) | 一种新型双层药物球囊导管 | |
US9656030B1 (en) | System for the injection of cells and/or biologically active materials into coronary arteries for therapeutic purposes | |
CN112439122A (zh) | 一种球囊扩张导管 | |
CN110575606A (zh) | 一种药物洗脱球囊扩张导管及使用方法 | |
CN102940543A (zh) | 一种载药球囊与支架构成的组合型医疗器械 | |
JP2022522469A (ja) | 組織を復元するための装置および方法 | |
CN106621001A (zh) | 药物可回收球囊导管 | |
CN209490364U (zh) | 一种球囊扩张型导引延长导管 | |
CN104105525A (zh) | 球囊导管*** | |
CN106137486A (zh) | 一种分叉球囊 | |
CN219423543U (zh) | 一种球囊导管 | |
CN203935501U (zh) | 一种药物球囊导管 | |
US11931536B2 (en) | Surface liquefied drug-coated balloon | |
KR20150102813A (ko) | 풍선 카테터 | |
CN209361621U (zh) | 药物球囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 518118 Guangdong province Shenzhen Pingshan New District Industrial Zone planning five road No. 1 Patentee after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: 518102 Guangdong Province, Shenzhen city Xixiang Street No 115 District 1 factories Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 518118, No. five, No. 1, great industrial zone, Ping Shan, Guangdong, Shenzhen Patentee after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: 518118 Guangdong province Shenzhen Pingshan New District Industrial Zone planning five road No. 1 Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 518118, No. five, No. 1, great industrial zone, Ping Shan, Guangdong, Shenzhen Patentee after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: 518118 Guangdong province Shenzhen Pingshan New District Industrial Zone planning five road No. 1 Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Xinlitai Medical Equipment Co.,Ltd. Address before: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |